Brookline Capital Management Estimates CervoMed Q2 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Brookline Capital Management issued their Q2 2025 earnings estimates for CervoMed in a research report issued to clients and investors on Tuesday, March 11th. Brookline Capital Management analyst T. Bussian anticipates that the company will post earnings per share of ($0.48) for the quarter. Brookline Capital Management currently has a “Hold” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q3 2025 earnings at ($0.38) EPS.

A number of other equities analysts also recently weighed in on CRVO. Morgan Stanley reissued an “underweight” rating on shares of CervoMed in a research note on Wednesday, December 11th. Roth Mkm lifted their target price on shares of CervoMed from $7.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group lowered their target price on shares of CervoMed from $65.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. HC Wainwright downgraded shares of CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of CervoMed in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.14.

CervoMed Stock Up 161.4 %

CRVO stock opened at $6.17 on Wednesday. The company has a fifty day moving average price of $2.30 and a 200-day moving average price of $8.20. CervoMed has a 52-week low of $1.80 and a 52-week high of $26.38.

Institutional Trading of CervoMed

Several hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its position in shares of CervoMed by 13.9% in the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after purchasing an additional 14,042 shares during the period. State Street Corp raised its position in shares of CervoMed by 28.1% in the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares during the period. Woodline Partners LP bought a new stake in shares of CervoMed in the fourth quarter valued at approximately $175,000. Perigon Wealth Management LLC bought a new stake in shares of CervoMed in the fourth quarter valued at approximately $147,000. Finally, Nuveen Asset Management LLC raised its position in shares of CervoMed by 113.6% in the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company’s stock valued at $97,000 after purchasing an additional 22,104 shares during the period. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.